Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 10, 2004, Pages 1681-1690

  Sakariassen, Kjell S ^a,d   Turitto, V T ^b   Baumgartner, H R ^c  

^a Serono International SA   (Switzerland)

^b ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^c RBM ^*  (Switzerland)

^d RBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGINYLGLYCYLASPARTYLSERINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 9A; CLOPIDOGREL; COLLAGENASE; COUMARIN; DESMOPRESSIN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; IODIXANOL; IOHEXOL; IOXAGLIC ACID; LINOTROBAN; LIPOCORTIN 5; NADROPARIN; OMEGA 3 FATTY ACID; PROTAMINE SULFATE; RETINOIC ACID; THROMBIN; THROMBOPLASTIN; TICLOPIDINE; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG;

ARTICLE; BALLOON CATHETER; BLEEDING DISORDER; BLEEDING TIME; BLOOD FLOW; BLOOD FLOW VELOCITY; BLOOD RHEOLOGY; BLOOD VESSEL WALL; CLINICAL TRIAL; CRYOPRECIPITATE; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; EQUIPMENT DESIGN; ERYTHROCYTE COUNT; FIBRIN DEPOSITION; FRANCE; HEART FAILURE; HEMOSTASIS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; VON WILLEBRAND DISEASE;

ANIMALS; BLOOD CELLS; ENDOTHELIUM, VASCULAR; HEMORHEOLOGY; HEMOSTASIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PERFUSION; RESEARCH; THROMBOSIS;

EID: 13244268264     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00907.x     Document Type: Article

References (71)

1. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
2. Hellem AJ. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960; 12 (Suppl. 51): 1-117.
3. Salzman EW. Measurement of platelet adhesiveness: a simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J Lab Clin Med 1963; 62: 724-35.
4. Baumgartner HR. Eine neue Methode zur Erzeuging von Thromben durch gezielte Uberdehnung der Gefasswand. Zeitschr Ges Exp Med 1963; 137: 227-47.
5. Baumgartner HR, Studer A. Folgen des Gefasskatheterismus am normo- und hypercholesterinaemischen Kaninchen. Path Microbiol 1966; 29: 393-405.
6. Ross R, Bornstein P. The elastin fiber. I. The separation and partial characterization of its macromolecular components. J Cell Biol 1969; 40: 366-81.
7. Stemerman MB, Baumgartner HR, Spaet TH. The subendothelial microfibril and platelet adhesion. Lab Invest 1971; 24: 179-86.
8. Baumgartner HR, Haudenschild C. Adhesion of platelets to subendothelium. Ann NY Acad Sci 1972; 201: 22-36.
9. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-79.
10. Baumgartner HR, Muggli R, Tschopp TB, Turitto VT. Platelet adhesion, release and aggregationin flowing blood: effects of surface properties and platelet function. Thromb Haemost 1976; 35: 124-38.
11. Baumgartner HR. Effects of anticoagulation on the interaction of human platelets with subendothelium in flowing blood. Schweiz Med Wochenschr 1976; 106: 1367-8.
12. Baumgartner HR, Sakariassen KS. Factors controlling thrombus formation on arterial lesions. Ann NY Acad Sci 1985; 454: 162-77.
13. Roux S, Sakariassen KS, Turitto VT, Baumgartner HR. Effect of aspirin and epinephrine on experimentally-induced thrombogenesis in dogs: a parallelism between in vivo and ex vivo thrombosis models. Arterioscler Thromb 1991; 11: 1182-91.
14. Baumgartner HR, Muggli R. Adhesion and aggregation: morphological demonstration and quantitation in vitro. In: Gordon JL, ed. Platelets in Biology and Pathology. Amsterdam: Elsevier/North Holland Biomedical Press, 1976; 2: 23-60.
15. Turitto VT, Baumgartner HR. Initial deposition of platelets and fibrin on vascular surfaces in flowing blood. In: Colman RW, Hirsh J, Marder VJ, Salzman JB, eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Philadelphia: JB Lippincott Co., 1994; 805-22.
16. Tschopp TB, Weiss HJ, Baumgartner HR. Decreased platelet adhesion of platelets to subendothelium in von Willebrand's disease. J Lab Clin Med 1974; 83: 296-300.
17. Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear-dependant decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome, J Lab Clin Med 1978; 92: 750-64.
18. Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D. Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand's disease. Blood 1978; 51: 267-79.
19. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adherence to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature 1979; 279 636-8.
20. Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of factor VIII-von Willebrand factor to human subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-76.
21. Sixma JJ, Sakariassen KS, Stel HV, Houdijk WPM, In der Maur DW, Hamer RJ, de Groot PG, van Mourik JA. Functional domains of von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen. J Clin Invest 1984; 74: 736-44.
22. Houdijk WPM, Sakariassen KS, Nievelstein PFEM, Sixma JJ. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest 1985; 75: 531-40.
23. Sakariassen KS, Niuwenhuis HK, Sixma JJ. Differentiation of patients with subtype IIb-like von Willebrand's disease by means of perfusion experiments by reconstituted blood. Br J Haematol 1985; 59: 459-70.
24. Sakariassen KS, Nievelstein PFEM, Coller B, Sixma JJ. The role of platelet membrane glycoprotein Ib and IIb/IIIa in platelet adherence to artery subendothelium. Br J Haematol 1986; 63: 681-91.
25. Weiss HJ, Turitto VT, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoprotein IIb-IIIa and storage granules. Blood 1986; 67: 322-31.
26. Sakariassen KS, Cattaneo M, van der Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64 1408-15.
27. Niuwenhuis HK, Akkerman JWN, Houdijk WPM, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985; 318: 470-2.
28. Niuwenhuis HK, Sakariassen K, Houdijk WPM, Nievelstein PFEM, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986; 68: 692-5.
29. Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 102: 522-35.
30. Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res 2001; 104: 149-74.
31. Stel HV, Sakariassen KS, Scholte BJ, van der Kwast TH, de Groot PG, Sixma JJ, van Mourik J. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood 1984; 63: 1408-15.
32. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90.
33. Baumgartner HR, Tschopp TB, Meyer D. Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor. Br J Haematol 1980; 44: 127-39.
34. Sakariassen KS, Fressinaud E, Girma JP, Meyer D, Baumgartner HR. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann NY Acad Sci 1987; 516: 118-30.
35. Sakariassen KS, Fressinaud E, Girma JP, Baumgartner HR, Meyer D. Mediation of platelet adhesion to fibrillar collagen in flowing blood by a proteolytic fragment of human von Willebrand factor. Blood 1986; 67: 1515-8.
36. Fressinaud E, Sakariassen KS, Rotschild C, Baumgartner HR, Meyer D. Shear dependent decrease of thrombus growth on collagen in non-anticoagulated blood from patients suffering von Willebrand disease and haemophilia A. Blood 1992; 80: 988-94.
37. Sakariassen KS, Joss R, Muggli R, Tschopp TB, Sage H, Baumgartner HR. Collagen type III induced ex vivo thrombogenesis in humans: role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1990; 19: 276-84.
38. Sakariassen KS, Kuhn H, Muggli R, Baumgartner HR. Growth and stability of thrombi in flowing blood: assessment of platelet surface interactions with computer-assisted morphometry. Thromb Haemost 1988; 60: 392-8.
39. Sakariassen KS, Baumgartner HR. Axial dependence of platelet-collagen interactions in flowing blood. Upstream thrombus growth impairs downstream platelet adhesion. Arteriosclerosis 1989; 9 33-42.
40. Gast AG, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 1994; 14: 466-74.
41. Kirchhofer D, Sakariassen KS, Clozel M, Tschopp TB, Hadvary P, Nemerson Y, Baumgartner HR. Relationship between tissue factor expression and deposition of fibrin, platelets and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood 1993; 81: 2050-8.
42. Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. In: Hawiger J, ed. Methods in Enzymology. New York: Academic Press Inc., 1989; 33-70.
43. Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial stimulation with tumor necrosis factor-alpha expresses varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 1994; 93: 2073-83.
44. Kirchhofer D, Tschopp TB, Baumgartner HR. Active-site blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb 1995; 15: 1098-106.
45. Kirchhofer D, Tschopp TB, Steiner B, Baumgartner HR. Role of collagen-adherent platelets in mediating fibrin formation in whole blood. Blood 1995; 86: 3815-22.
46. Barstad RM, Roald HE, Cui W, Turitto VT, Sakariassen KS. A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenoses. Arterioscler Thromb 1994; 14: 1984-91.
47. Holme PA, Orvim U, Hamers MJAG, Solum NO, Brosstad FR, Barstad RM, Sakariassen KS. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with severe stenoses. Arterioscler Thromb Vasc Biol 1997; 17: 646-53.
48. Orvim U, Barstad RM, Vlasuk GP, Sakariassen KS. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear dependent thrombus formation. Arterioscler Thromb Vasc Biol 1995; 15: 2188-94.
49. Hanson SR, Sakariassen KS. Blood flow and antithrombotic drug effects. Am Heart J 1998; 135: S132-45.
50. Orvim U, Barstad RM, Orning L, Petersen LB, Ezban M, Hedner U, Sakariassen KS. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear rate dependent in human blood. Arterioscler Thromb Vasc Biol 1997; 17: 3049-56.
51. Orning L, Hu CK, Agner E, Engebretsen M, Fischer PM, Petersen LB, Orvim U, Llinas M, Sakariassen KS. A cyclic pentapeptide derived from the EGF-2 like domain of factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. Thromb Haemost 2002; 87: 13-21.
52. Bossavy JP, Sakariassen KS, Rubsamen K, Thalamas C, Boneu B, Cadroy Y. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of experimental arterial thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 1348-53.
53. van Heerde WL, Sakariassen KS, Hemker HC, Sixma JJ, Reutlingsberger CCPM, de Groot PG. Annexin V inhibits the procoagulant activity of TNF-stimulated endothelial cells under flow conditions. Arterioscler Thromb 1994; 14: 824-30.
54. Aznar-Salatti J, Anton P, Nemerson Y, Sakariassen KS. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide arg-gly-asp-val. Experiments with flowing non-anticoagulated blood. Blood Coag Finbrinolysis 1993; 4: 881-90.
55. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents fibrin deposition on procoagulant subendothelial matrix when exposed to flowing non-anticoagulated human blood. Blood Coag Fibrinolysis 1994; 5 755-60.
56. Barstad RM, Stephens RW, Hamers MJAG, Sakariassen KS. Protamin sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost 2000; 83: 334-7.
57. Barstad RM, Hamers MJAG, Stephens RW, Sakariassen KS. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa dependent thrombus formation. Blood 1995; 86 212-8.
58. Sakariassen KS, Barstad RM, Hamers MJAG, Stormorken H. Iohexol, platelet activation and thrombosis. I. Iohexol-induced platelet secretion does not affect thrombus formation in native blood. Acta Radiol 1998; 39: 349-54.
59. Sakariassen KS, Buchmann M, Hamers MJAG, Stormorken H. Iohexol, platelet activation and thrombosis. II. Iohexol-induced platelet secretion does not affect collagen- or tissue factor-induced thrombus formation in blood anticoagulated with heparin and aspirin. Acta Radiol 1998; 39: 355-61.
60. Roald HE, Barstad RM, Engen A, Kierulf P, Skjorten F, Sakariassen KS. HN-11500 - a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost 1994; 71: 103-9.
61. Roald HE, Barstad RM, Kierulf P, Skjorten F, Dickinson JP, Kieffer G, Sakariassen KS. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in human non-anticoagulated blood independently of the blood flow conditions. Thromb Haemost 1994; 71: 665-72.
62. Barstad RM, Orvim U, Hamers MJAG, Tjonnfjord GE, Brosstad F, Sakariassen KS. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemost 1996; 75 827-32.
63. Roald HE, Orvim U, Bakken IJ, Barstad RM, Kierulf P, Sakariassen KS. Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. Arterioscler Thromb 1994; 14: 617-21.
64. Barstad RM, Roald HE, Petersen LB, Stokke KT, Kierulf P, Sakariassen KS. No effect of daily dietary supplement of 2.4 g Omega-3 fatty acids on acute platelet-dependent thrombus formation in flowing non-anticoagulated blood. Blood Coag Fibrinolysis 1995; 6: 374-81.
65. Diquelou A, Dupoy D, Cariou R, Sakariassen KS, Borten B, Cadroy Y. A comparative study of the anticoagulant and antithrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental human venous thrombosis model. Thromb Haemost 1995; 74: 1286-92.
66. Bossavy JP, Thalamas C, Sagnard L, Barret A, Sakariassen KS, Boneu B, Cadroy Y. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92 1518-25.
67. Bossavy JP, Cadroy Y, Sakariassen KS, Boneu B, Barret A. Non-fractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model. Ann Vasc Surg 1999; 13: 393-401.
68. Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis. Effect of anticoagulation level and combination therapy with aspirin. Arterioscler Thromb Vasc Biol 1999; 19: 2269-75.
69. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen KS, Boneu B. Early potential antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombosis in humans. Circulation 2000; 101: 2823-8.
70. Orvim U, Barstad RM, Stormorken H, Hamers MJAG, Petersen LB, Sakariassen KS. Immunological quantification of fibrin deposition in thrombi formed in flowing native human blood. Br J Haematol 1996; 95: 389-98.
71. Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost 1998; 79: 162-8.